The US FDA approved Merck's sotatercept (Winrevair) as the first activin signaling inhibitor therapy for pulmonary arterial hypertension.

The US FDA has approved Merck's treatment for adults with high blood pressure due to constriction of lung arteries, a rare condition known as pulmonary arterial hypertension. The drug, called sotatercept and marketed as Winrevair, is the first FDA-approved activin signaling inhibitor therapy for PAH, a progressive and life-threatening lung condition that affects around 40,000 people in the US. The approval is a win for both the drugmaker and for patients suffering from the rare disease.

March 26, 2024
24 Articles

Further Reading